
Research update, DanCann Pharma Q2 2021: Transformative acquisition adds great value

Carlsquare Equity Research has updated its research report on DanCann Pharma.

Interesting acquisition brings shortcut to the market.

[Read the full analysis here.](#)

About Carlsquare

Carlsquare is a Pan-European research firm and financial advisor, focusing on M&A, Equity Research and Growth Equity. Carlsquare has 80+ employees with deep sector knowledge in all 11 GICS sectors. The senior equity research team have an extensive experience about the stock environment and several business sectors. The team produces company research reports, independent valuations and trading notes. The group have offices in Berlin, Copenhagen, Hamburg, London, Munich and Stockholm. [Read more](#)

Contact

MARKUS AUGUSTSSON
Head of Equity Research
markus.augustsson@carlsquare.com
+46 (0)76 235 03 20

Contacts

MARKUS AUGUSTSSON

Head of Equity Research
markus.augustsson@carlsquare.com
+46 (0)76 235 03 20

JONATAN ANDERSSON

Equity Analyst
jonatan.andersson@carlsquare.com
+46 (0)70 508 00 51

Attachments

[Research update, DanCann Pharma Q2 2021: Transformative acquisition adds great value](#)